Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 18.

Roelcke, U; Wyss, M T; Nowosielski, M; Rudà, R; Roth, P; Hofer, S; Galldiks, N; Crippa, F; Weller, M; Soffietti, R (2016). Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-Oncology, 18(5):744-751.

Gramatzki, Dorothee; Roth, P; Felsberg, J; Hofer, S; Rushing, E J; Hentschel, B; Westphal, M; Krex, D; Simon, M; Schnell, O; Wick, W; Reifenberger, G; Weller, M (2016). Chemotherapy for intracranial ependymoma in adults. BMC Cancer, 16(1):287.

Feilchenfeldt, J; Varga, Z; Siano, M; Grabsch, H I; Held, U; Schuknecht, B; Trip, A; Hamaguchi, T; Gut, P; Balague, O; Khanfir, K; Diebold, J; Jochum, W; Shoji, H; Kushima, R; Wagner, D; Shimada, Y; Cats, A; Knuth, A; Moch, H; Aebi, S; Hofer, S (2015). Corrigendum: Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 113(12):1747.

Feilchenfeldt, J; Varga, Z; Siano, M; Grabsch, H I; Held, U; Schuknecht, B; Trip, A; Hamaguchi, T; Gut, P; Balague, O; Khanfir, K; Diebold, J; Jochum, W; Shoji, H; Kushima, R; Wagner, D; Shimada, Y; Cats, A; Knuth, A; Moch, H; Aebi, S; Hofer, S (2015). Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 113(5):716-721.

Woernle, C M; Péus, D; Hofer, S; Rushing, E J; Held, U; Bozinov, O; Krayenbühl, N; Weller, M; Regli, L (2015). Efficacy of surgery and further treatment of progressive glioblastoma. World Neurosurgery, 84(2):301-307.

Valko, P O; Siddique, A; Linsenmeier, C; Zaugg, K; Held, U; Hofer, S (2015). Prevalence and predictors of fatigue in glioblastoma: a prospective study. Neuro-Oncology, 17(2):274-281.

Hofer, S; Mengele, K; Stemmler, H J; Schmitt, M; Pestalozzi, B (2012). Intrathecal trastuzumab: dose matters. Acta Oncologica, 51(7):955-956.

Riklin, C; Seystahl, K; Hofer, S; Happold, C; Winterhalder, R; Weller, M (2012). Antiangiogenic treatment for multiple CNS hemangioblastomas. Onkologie, 35(7-8):443-445.

Hofer, S; Marosi, C (2012). News from the Neuro-Oncology front. memo - Magazine of European Medical Oncology, 5(3):169-170.

Oehler, C; Frei, K; Rushin, E J; McSheehy, P M J; Weber, D; Allegrini, P R; Weniger, D; Lütolf, U M; Knuth, A; Yonekawa, Y; Barath, K; Broggini-Tenzer, A; Pruschy, M; Hofer, S (2012). Patupilone (Epothilone B) for recurrent glioblastoma: Clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology, 83(1):1-9.

Hegi, M E; Diserens, A C; Bady, P; Kamoshima, Y; Kouwenhoven, M C; Delorenzi, M; Lambiv, W L; Hamou, M F; Matter, M S; Koch, A; Heppner, F L; Yonekawa, Y; Merlo, A; Frei, K; Mariani, L; Hofer, S (2011). Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib - a phase II trial. Molecular Cancer Therapeutics, 10(6):1102-1112.

Roth, P; Wischhusen, J; Happold, C; Chandran, P A; Hofer, S; Eisele, G; Weller, M; Keller, A (2011). A specific miRNA signature in the peripheral blood of glioblastoma patients. Journal of Neurochemistry, 118(3):449-457.

Wick, A; Dörner, N; Schäfer, N; Hofer, S; Heiland, S; Schemmer, D; Platten, M; Weller, M; Bendszus, M; Wick, W (2011). Bevacizumab does not increase the risk of remote relapse in malignant glioma. Annals of Neurology, 69(3):586-592.

Hofer, S; Elandt, K; Greil, R; Hottinger, A F; Huber, U; Lemke, D; Marosi, C; Ochsenbein, A; Pichler, J; Roelcke, U; Weder, P; Zander, T; Wick, W; Weller, M (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncologica, 50(5):630-635.

Hofer, S; Linnebank, M; Weller, M; Bahmanyar, S; Montgomery, S M; Hillert, J; Ekbom, A; Olsson, T (2010). Cancer risk among patients with multiple sclerosis and their parents. Neurology, 74(7):614-615; author reply 615.

Hofer, S; Happold, C; Weller, M (2010). Oligodendroglioma. In: Tonn, J C; Westphal, M; Rutka, J T. Oncology of CNS Tumors. Berlin, Heidelberg : Springer, 163-170.

Hofer, S; Kollias, S; Weller, M (2009). Evolution of glioblastoma. Acta Oncologica, 48(4):630-631.

Wyss, M; Hofer, S; Bruehlmeier, M; Hefti, M; Uhlmann, C; Bärtschi, E; Buettner, U W; Roelcke, U (2009). Early metabolic responses in temozolomide treated low-grade glioma patients. Journal of Neuro-Oncology, 95(1):87-93.

This list was generated on Sat Nov 18 12:13:36 2017 CET.